STOCK TITAN

Veraxa Biotech - Post de-SPAC (VRXA) SEC Filings, Jun 9, 2026

VRXA NASDAQ
Rhea-AI Summary

Veraxa Biotech Holding AG director and Chief Executive Officer Christoph Rudiger Antz has filed an initial Form 3 as an insider of the company. The filing identifies his roles but does not report any transactions or share holdings, with all transaction and holding counts shown as zero.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
insider
-
Rhea-AI Summary

Veraxa Biotech Holding AG officer Heinz Schwer has filed a Form 3 as Chief Business Officer of VRXA. This is an initial statement of beneficial ownership and shows no reported transactions, with no shares bought, sold, acquired, or disposed of in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
insider
-
Rhea-AI Summary

Veraxa Biotech Holding AG executive Buergermeister Torsten Georg Friedrich, the company’s Chief Financial Officer, has filed an initial Form 3 as an officer of the company. The data provided does not list any reportable transactions or holdings, indicating this filing is primarily an initial ownership disclosure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
insider

FAQ

How many Veraxa Biotech - Post de-SPAC (VRXA) SEC filings are available on StockTitan?

StockTitan tracks 33 SEC filings for Veraxa Biotech - Post de-SPAC (VRXA), including 20-F annual reports and 6-K reports. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Veraxa Biotech - Post de-SPAC (VRXA)?

The most recent SEC filing for Veraxa Biotech - Post de-SPAC (VRXA) was filed on November 19, 2026.